ESMO E-Learning: The Use of Biomarkers for Treatment Decisions in Oncology

New E-Learning module by Profs Yap and Josephs now available. View the presentation and take the CME test today!

Learning objectives

  • To understand the definition and classification of biomarkers
  • To understand the potential uses of biomarker applications in anti-cancer drug development  
  • To learn about particular examples of biomarker applications in the processes of drug development

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
The Use of Biomarkers for Treatment Decisions in Oncology 30 min. 48 slides - -

According to the definition adopted by the US National Institutes of Health Biomarkers Definitions Working Group, a biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. Biomarkers are key components of translational studies. Translation of molecular insights into useful therapeutic approaches is highly complex. Ideally, the development of targeted therapies should be closely coupled with the identification and validation of biomarkers, thus maximising the potential for rational development of such agents based on rigorous mechanistic assessment of their effects. Such information can be used throughout drug discovery, screening, preclinical and throughout all phases of clinical testing.

This E-learning module addresses the potential uses of biomarkers to facilitate the development of anti-cancer drugs. It provides general approaches to the definition, classification and evaluation of biomarkers, as well as applications in drug development from the specific aspects of target discovery and validation and applications in different phases of clinical studies. Furthermore, particular examples from the recent development of anti-cancer, biologic and immunotherapeutic agents are provided.

This E-Learning module was published in 2015 and expired in 2017.

Last update: 17 Aug 2015

The authors have reported no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings